Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Divestments (2016 - 2025)

Historic Divestments for Dr Reddys Laboratories (RDY) over the last 14 years, with Q2 2025 value amounting to -$224.3 million.

  • Dr Reddys Laboratories' Divestments rose 761.11% to -$224.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$307.6 million, marking a year-over-year decrease of 12288.31%. This contributed to the annual value of $5.4 million for FY2024, which is N/A changed from last year.
  • Per Dr Reddys Laboratories' latest filing, its Divestments stood at -$224.3 million for Q2 2025, which was up 761.11% from -$242.7 million recorded in Q2 2024.
  • Dr Reddys Laboratories' Divestments' 5-year high stood at $313.6 million during Q1 2024, with a 5-year trough of -$321.7 million in Q4 2022.
  • Over the past 5 years, Dr Reddys Laboratories' median Divestments value was -$69.9 million (recorded in 2021), while the average stood at -$69.6 million.
  • Its Divestments has fluctuated over the past 5 years, first surged by 42018.61% in 2021, then tumbled by 77292.34% in 2022.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Divestments stood at -$36.8 million in 2021, then plummeted by 772.92% to -$321.7 million in 2022, then soared by 52.03% to -$154.3 million in 2023, then plummeted by 57.32% to -$242.7 million in 2024, then rose by 7.61% to -$224.3 million in 2025.
  • Its Divestments stands at -$224.3 million for Q2 2025, versus -$242.7 million for Q2 2024 and $313.6 million for Q1 2024.